文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

真实队列中射血分数保留的心力衰竭伴糖尿病患者的表型和预后。

Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.

机构信息

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc and Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Cardiovascular Division, Université Catholique de Louvain, Avenue Hippocrate, 10, 1200, Brussels, Belgium.

出版信息

Cardiovasc Diabetol. 2021 Feb 19;20(1):48. doi: 10.1186/s12933-021-01242-5.


DOI:10.1186/s12933-021-01242-5
PMID:33608002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7893869/
Abstract

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome, with several underlying etiologic and pathophysiologic factors. The presence of diabetes might identify an important phenotype, with implications for therapeutic strategies. While diabetes is associated with worse prognosis in HFpEF, the prognostic impact of glycemic control is yet unknown. Hence, we investigated phenotypic differences between diabetic and non-diabetic HFpEF patients (pts), and the prognostic impact of glycated hemoglobin (HbA1C). METHODS: We prospectively enrolled 183 pts with HFpEF (78 ± 9 years, 38% men), including 70 (38%) diabetics (type 2 diabetes only). They underwent 2D echocardiography (n = 183), cardiac magnetic resonance (CMR) (n = 150), and were followed for a combined outcome of all-cause mortality and first HF hospitalization. The prognostic impact of diabetes and glycemic control were determined with Cox proportional hazard models, and illustrated by adjusted Kaplan Meier curves. RESULTS: Diabetic HFpEF pts were younger (76 ± 9 vs 80 ± 8 years, p = 0.002), more obese (BMI 31 ± 6 vs 27 ± 6 kg/m, p = 0.001) and suffered more frequently from sleep apnea (18% vs 7%, p = 0.032). Atrial fibrillation, however, was more frequent in non-diabetic pts (69% vs 53%, p = 0.028). Although no echocardiographic difference could be detected, CMR analysis revealed a trend towards higher LV mass (66 ± 18 vs 71 ± 14 g/m, p = 0.07) and higher levels of fibrosis (53% vs 36% of patients had ECV by T1 mapping > 33%, p = 0.05) in diabetic patients. Over 25 ± 12 months, 111 HFpEF pts (63%) reached the combined outcome (24 deaths and 87 HF hospitalizations). Diabetes was a significant predictor of mortality and hospitalization for heart failure (HR: 1.72 [1.1-2.6], p = 0.011, adjusted for age, BMI, NYHA class and renal function). In diabetic patients, lower levels of glycated hemoglobin (HbA1C < 7%) were associated with worse prognosis (HR: 2.07 [1.1-4.0], p = 0.028 adjusted for age, BMI, hemoglobin and NT-proBNP levels). CONCLUSION: Our study highlights phenotypic features characterizing diabetic patients with HFpEF. Notably, they are younger and more obese than their non-diabetic counterpart, but suffer less from atrial fibrillation. Although diabetes is a predictor of poor outcome in HFpEF, intensive glycemic control (HbA1C < 7%) in diabetic patients is associated with worse prognosis.

摘要

背景:射血分数保留的心力衰竭(HFpEF)是一种异质性综合征,存在多种潜在的病因和病理生理因素。糖尿病的存在可能会识别出一个重要的表型,这对治疗策略有影响。虽然糖尿病与 HFpEF 的预后较差相关,但血糖控制的预后影响尚不清楚。因此,我们研究了糖尿病和非糖尿病 HFpEF 患者(pts)之间的表型差异,以及糖化血红蛋白(HbA1C)的预后影响。

方法:我们前瞻性纳入了 183 例 HFpEF 患者(78±9 岁,38%为男性),其中 70 例(38%)为糖尿病患者(仅 2 型糖尿病)。他们接受了 2 维超声心动图(n=183)、心脏磁共振(CMR)(n=150)检查,并随访了所有原因死亡和首次 HF 住院的复合结局。使用 Cox 比例风险模型确定糖尿病和血糖控制的预后影响,并通过调整后的 Kaplan-Meier 曲线进行说明。

结果:糖尿病 HFpEF 患者更年轻(76±9 岁 vs 80±8 岁,p=0.002),更肥胖(BMI 31±6 千克/平方米 vs 27±6 千克/平方米,p=0.001),更常患有睡眠呼吸暂停(18% vs 7%,p=0.032)。然而,非糖尿病患者中房颤更为常见(69% vs 53%,p=0.028)。尽管在超声心动图上没有发现差异,但 CMR 分析显示,糖尿病患者的左心室质量(66±18 克/平方米 vs 71±14 克/平方米,p=0.07)和纤维化水平(53%的患者通过 T1 映射的 ECV>33%,而 36%的患者,p=0.05)呈上升趋势。在 25±12 个月的随访中,111 例 HFpEF 患者(63%)达到了复合结局(24 例死亡和 87 例 HF 住院)。糖尿病是死亡和心力衰竭住院的显著预测因素(HR:1.72 [1.1-2.6],p=0.011,调整了年龄、BMI、NYHA 分级和肾功能)。在糖尿病患者中,糖化血红蛋白(HbA1C<7%)水平较低与预后较差相关(HR:2.07 [1.1-4.0],p=0.028,调整了年龄、BMI、血红蛋白和 NT-proBNP 水平)。

结论:我们的研究强调了糖尿病 HFpEF 患者的表型特征。值得注意的是,与非糖尿病患者相比,他们更年轻、更肥胖,但房颤发病率较低。尽管糖尿病是 HFpEF 不良预后的预测因素,但糖尿病患者强化血糖控制(HbA1C<7%)与预后较差相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/f424b9bcfd1b/12933_2021_1242_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/a12e3340fc58/12933_2021_1242_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/ad867ae863cd/12933_2021_1242_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/c9aa7b09ebf2/12933_2021_1242_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/f424b9bcfd1b/12933_2021_1242_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/a12e3340fc58/12933_2021_1242_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/ad867ae863cd/12933_2021_1242_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/c9aa7b09ebf2/12933_2021_1242_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58be/7893869/f424b9bcfd1b/12933_2021_1242_Fig4_HTML.jpg

相似文献

[1]
Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.

Cardiovasc Diabetol. 2021-2-19

[2]
Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study.

Cardiovasc Diabetol. 2020-5-2

[3]
Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus.

Cardiovasc Diabetol. 2021-9-8

[4]
Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI.

Cardiovasc Diabetol. 2024-4-29

[5]
Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus.

Cardiovasc Diabetol. 2018-6-30

[6]
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.

Circ Heart Fail. 2016-1

[7]
Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction.

ESC Heart Fail. 2020-10

[8]
Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction.

J Cardiovasc Magn Reson. 2018-8-8

[9]
Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.

J Am Heart Assoc. 2019-8-21

[10]
Long-term outcomes prediction in diabetic heart failure with preserved ejection fraction by cardiac MRI.

Eur Radiol. 2024-9

引用本文的文献

[1]
Cardiac digital twins: a tool to investigate the function and treatment of the diabetic heart.

Cardiovasc Diabetol. 2025-7-18

[2]
The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications.

Cardiovasc Diabetol. 2025-4-28

[3]
Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF.

Cardiovasc Diabetol. 2025-4-4

[4]
Prevalence and prognostic significance of reduced myocardial perfusion reserve in diabetic heart failure with preserved ejection fraction using quantitative perfusion cardiac magnetic resonance.

Eur Radiol. 2025-3-5

[5]
Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats.

Sci Rep. 2025-2-11

[6]
Myocardial Abnormalities Across the AHA/ACC Stages of Heart Failure in Patients With Diabetes.

JACC Asia. 2024-10-22

[7]
J-shaped association between serum glucose potassium ratio and prognosis in heart failure with preserved ejection fraction with stronger predictive value in non-diabetic patients.

Sci Rep. 2024-12-2

[8]
Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF.

Rev Cardiovasc Med. 2023-2-8

[9]
New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.

Int J Mol Sci. 2024-4-17

[10]
Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model.

Cardiovasc Res. 2025-4-22

本文引用的文献

[1]
The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis.

Heart Lung Circ. 2021-5

[2]
Meta-Analysis of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.

Heart Lung Circ. 2021-5

[3]
Myocardial glucotoxicity: Mechanisms and potential therapeutic targets.

Arch Cardiovasc Dis. 2020-11-12

[4]
Type 2 diabetes is an independent predictor of lowered peak aerobic capacity in heart failure patients with non-reduced or reduced left ventricular ejection fraction.

Cardiovasc Diabetol. 2020-9-19

[5]
Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis.

Cardiovasc Diabetol. 2020-8-5

[6]
Ventricular-vascular coupling in heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Heart Lung. 2021

[7]
Heart failure with preserved ejection fraction in Belgium: characteristics and outcome of a real-life cohort.

Acta Cardiol. 2021-9

[8]
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.

Eur J Heart Fail. 2020-11

[9]
Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.

Cardiovasc Diabetol. 2020-5-28

[10]
Basic Mechanisms of Diabetic Heart Disease.

Circ Res. 2020-5-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索